Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
eLife Sciences Publications Ltd
2021-11-01
|
| Series: | eLife |
| Subjects: | |
| Online Access: | https://elifesciences.org/articles/70330 |
| _version_ | 1818026771539296256 |
|---|---|
| author | Marloes Grobben Karlijn van der Straten Philip JM Brouwer Mitch Brinkkemper Pauline Maisonnasse Nathalie Dereuddre-Bosquet Brent Appelman AH Ayesha Lavell Lonneke A van Vught Judith A Burger Meliawati Poniman Melissa Oomen Dirk Eggink Tom PL Bijl Hugo DG van Willigen Elke Wynberg Bas J Verkaik Orlane JA Figaroa Peter J de Vries Tessel M Boertien Amsterdam UMC COVID-19 S3/HCW study group Marije K Bomers Jonne J Sikkens Roger Le Grand Menno D de Jong Maria Prins Amy W Chung Godelieve J de Bree Rogier W Sanders Marit J van Gils |
| author_facet | Marloes Grobben Karlijn van der Straten Philip JM Brouwer Mitch Brinkkemper Pauline Maisonnasse Nathalie Dereuddre-Bosquet Brent Appelman AH Ayesha Lavell Lonneke A van Vught Judith A Burger Meliawati Poniman Melissa Oomen Dirk Eggink Tom PL Bijl Hugo DG van Willigen Elke Wynberg Bas J Verkaik Orlane JA Figaroa Peter J de Vries Tessel M Boertien Amsterdam UMC COVID-19 S3/HCW study group Marije K Bomers Jonne J Sikkens Roger Le Grand Menno D de Jong Maria Prins Amy W Chung Godelieve J de Bree Rogier W Sanders Marit J van Gils |
| author_sort | Marloes Grobben |
| collection | DOAJ |
| description | Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of cross-reactive antibodies against the spike (S) proteins of human coronaviruses (hCoV) after SARS-CoV-2 infection and vaccination. We found an 11- to 123-fold increase in antibodies binding to SARS-CoV and MERS-CoV as well as a 2- to 4-fold difference in antibodies binding to seasonal hCoVs in COVID-19 convalescent sera compared to pre-pandemic healthy donors, with the S2 subdomain of the S protein being the main target for cross-reactivity. In addition, we detected cross-reactive antibodies to all hCoV S proteins after SARS-CoV-2 vaccination in macaques and humans, with higher responses for hCoV more closely related to SARS-CoV-2. These findings support the feasibility of and provide guidance for development of a pan-coronavirus vaccine. |
| first_indexed | 2024-12-10T04:37:18Z |
| format | Article |
| id | doaj.art-355bde8c5cd74382bd903bb187245f09 |
| institution | Directory Open Access Journal |
| issn | 2050-084X |
| language | English |
| last_indexed | 2024-12-10T04:37:18Z |
| publishDate | 2021-11-01 |
| publisher | eLife Sciences Publications Ltd |
| record_format | Article |
| series | eLife |
| spelling | doaj.art-355bde8c5cd74382bd903bb187245f092022-12-22T02:01:59ZengeLife Sciences Publications LtdeLife2050-084X2021-11-011010.7554/eLife.70330Cross-reactive antibodies after SARS-CoV-2 infection and vaccinationMarloes Grobben0https://orcid.org/0000-0002-1559-9592Karlijn van der Straten1https://orcid.org/0000-0001-6373-9302Philip JM Brouwer2https://orcid.org/0000-0002-2902-7739Mitch Brinkkemper3Pauline Maisonnasse4Nathalie Dereuddre-Bosquet5Brent Appelman6AH Ayesha Lavell7Lonneke A van Vught8Judith A Burger9Meliawati Poniman10Melissa Oomen11Dirk Eggink12Tom PL Bijl13Hugo DG van Willigen14Elke Wynberg15Bas J Verkaik16Orlane JA Figaroa17Peter J de Vries18Tessel M Boertien19Amsterdam UMC COVID-19 S3/HCW study groupMarije K Bomers20Jonne J Sikkens21Roger Le Grand22Menno D de Jong23Maria Prins24Amy W Chung25Godelieve J de Bree26Rogier W Sanders27Marit J van Gils28https://orcid.org/0000-0003-3422-8161Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands; Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsCenter for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, INSERM, CEA, Fontenay-aux-Roses, FranceCenter for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, INSERM, CEA, Fontenay-aux-Roses, FranceCenter for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsDepartment of Internal Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsCenter for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsNational Institute for Public Health and the Environment, RIVM, Bilthoven, NetherlandsDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsDepartment of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands; Department of Infectious Diseases, Public Health Service of Amsterdam, GGD, Amsterdam, NetherlandsDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsDepartment of Internal Medicine, Tergooi Hospital, Amsterdam, NetherlandsDepartment of Internal Medicine, Tergooi Hospital, Amsterdam, NetherlandsDepartment of Internal Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsDepartment of Internal Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsCenter for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, INSERM, CEA, Fontenay-aux-Roses, FranceDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsDepartment of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands; Department of Infectious Diseases, Public Health Service of Amsterdam, GGD, Amsterdam, NetherlandsDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Victoria, AustraliaDepartment of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, United StatesDepartment of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, NetherlandsCurrent SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of cross-reactive antibodies against the spike (S) proteins of human coronaviruses (hCoV) after SARS-CoV-2 infection and vaccination. We found an 11- to 123-fold increase in antibodies binding to SARS-CoV and MERS-CoV as well as a 2- to 4-fold difference in antibodies binding to seasonal hCoVs in COVID-19 convalescent sera compared to pre-pandemic healthy donors, with the S2 subdomain of the S protein being the main target for cross-reactivity. In addition, we detected cross-reactive antibodies to all hCoV S proteins after SARS-CoV-2 vaccination in macaques and humans, with higher responses for hCoV more closely related to SARS-CoV-2. These findings support the feasibility of and provide guidance for development of a pan-coronavirus vaccine.https://elifesciences.org/articles/70330antibodiesSARS-CoV-2coronaviruscross-reactivityvaccineCOVID-19 |
| spellingShingle | Marloes Grobben Karlijn van der Straten Philip JM Brouwer Mitch Brinkkemper Pauline Maisonnasse Nathalie Dereuddre-Bosquet Brent Appelman AH Ayesha Lavell Lonneke A van Vught Judith A Burger Meliawati Poniman Melissa Oomen Dirk Eggink Tom PL Bijl Hugo DG van Willigen Elke Wynberg Bas J Verkaik Orlane JA Figaroa Peter J de Vries Tessel M Boertien Amsterdam UMC COVID-19 S3/HCW study group Marije K Bomers Jonne J Sikkens Roger Le Grand Menno D de Jong Maria Prins Amy W Chung Godelieve J de Bree Rogier W Sanders Marit J van Gils Cross-reactive antibodies after SARS-CoV-2 infection and vaccination eLife antibodies SARS-CoV-2 coronavirus cross-reactivity vaccine COVID-19 |
| title | Cross-reactive antibodies after SARS-CoV-2 infection and vaccination |
| title_full | Cross-reactive antibodies after SARS-CoV-2 infection and vaccination |
| title_fullStr | Cross-reactive antibodies after SARS-CoV-2 infection and vaccination |
| title_full_unstemmed | Cross-reactive antibodies after SARS-CoV-2 infection and vaccination |
| title_short | Cross-reactive antibodies after SARS-CoV-2 infection and vaccination |
| title_sort | cross reactive antibodies after sars cov 2 infection and vaccination |
| topic | antibodies SARS-CoV-2 coronavirus cross-reactivity vaccine COVID-19 |
| url | https://elifesciences.org/articles/70330 |
| work_keys_str_mv | AT marloesgrobben crossreactiveantibodiesaftersarscov2infectionandvaccination AT karlijnvanderstraten crossreactiveantibodiesaftersarscov2infectionandvaccination AT philipjmbrouwer crossreactiveantibodiesaftersarscov2infectionandvaccination AT mitchbrinkkemper crossreactiveantibodiesaftersarscov2infectionandvaccination AT paulinemaisonnasse crossreactiveantibodiesaftersarscov2infectionandvaccination AT nathaliedereuddrebosquet crossreactiveantibodiesaftersarscov2infectionandvaccination AT brentappelman crossreactiveantibodiesaftersarscov2infectionandvaccination AT ahayeshalavell crossreactiveantibodiesaftersarscov2infectionandvaccination AT lonnekeavanvught crossreactiveantibodiesaftersarscov2infectionandvaccination AT judithaburger crossreactiveantibodiesaftersarscov2infectionandvaccination AT meliawatiponiman crossreactiveantibodiesaftersarscov2infectionandvaccination AT melissaoomen crossreactiveantibodiesaftersarscov2infectionandvaccination AT dirkeggink crossreactiveantibodiesaftersarscov2infectionandvaccination AT tomplbijl crossreactiveantibodiesaftersarscov2infectionandvaccination AT hugodgvanwilligen crossreactiveantibodiesaftersarscov2infectionandvaccination AT elkewynberg crossreactiveantibodiesaftersarscov2infectionandvaccination AT basjverkaik crossreactiveantibodiesaftersarscov2infectionandvaccination AT orlanejafigaroa crossreactiveantibodiesaftersarscov2infectionandvaccination AT peterjdevries crossreactiveantibodiesaftersarscov2infectionandvaccination AT tesselmboertien crossreactiveantibodiesaftersarscov2infectionandvaccination AT amsterdamumccovid19s3hcwstudygroup crossreactiveantibodiesaftersarscov2infectionandvaccination AT marijekbomers crossreactiveantibodiesaftersarscov2infectionandvaccination AT jonnejsikkens crossreactiveantibodiesaftersarscov2infectionandvaccination AT rogerlegrand crossreactiveantibodiesaftersarscov2infectionandvaccination AT mennoddejong crossreactiveantibodiesaftersarscov2infectionandvaccination AT mariaprins crossreactiveantibodiesaftersarscov2infectionandvaccination AT amywchung crossreactiveantibodiesaftersarscov2infectionandvaccination AT godelievejdebree crossreactiveantibodiesaftersarscov2infectionandvaccination AT rogierwsanders crossreactiveantibodiesaftersarscov2infectionandvaccination AT maritjvangils crossreactiveantibodiesaftersarscov2infectionandvaccination |